These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37490408)

  • 1. Chamelogk: A Chromatographic Chameleonicity Quantifier to Design Orally Bioavailable Beyond-Rule-of-5 Drugs.
    Garcia Jimenez D; Vallaro M; Rossi Sebastiano M; Apprato G; D'Agostini G; Rossetti P; Ermondi G; Caron G
    J Med Chem; 2023 Aug; 66(15):10681-10693. PubMed ID: 37490408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updating the portfolio of physicochemical descriptors related to permeability in the beyond the rule of 5 chemical space.
    Ermondi G; Vallaro M; Goetz G; Shalaeva M; Caron G
    Eur J Pharm Sci; 2020 Apr; 146():105274. PubMed ID: 32088315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexibility in early drug discovery: focus on the beyond-Rule-of-5 chemical space.
    Caron G; Digiesi V; Solaro S; Ermondi G
    Drug Discov Today; 2020 Apr; 25(4):621-627. PubMed ID: 31991117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell permeability beyond the rule of 5.
    Matsson P; Doak BC; Over B; Kihlberg J
    Adv Drug Deliv Rev; 2016 Jun; 101():42-61. PubMed ID: 27067608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape.
    Price E; Weinheimer M; Rivkin A; Jenkins G; Nijsen M; Cox PB; DeGoey D
    J Med Chem; 2024 Apr; 67(7):5683-5698. PubMed ID: 38498697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing Soluble PROTACs: Strategies and Preliminary Guidelines.
    García Jiménez D; Rossi Sebastiano M; Vallaro M; Mileo V; Pizzirani D; Moretti E; Ermondi G; Caron G
    J Med Chem; 2022 Oct; 65(19):12639-12649. PubMed ID: 35469399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing Experimental 3D Structures in the Beyond-Rule-of-5 Chemical Space: The Case of Rifampicin.
    Ermondi G; Lavore F; Vallaro M; Tiana G; Vasile F; Caron G
    Chemistry; 2021 Jul; 27(40):10394-10404. PubMed ID: 34114271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are we ready to design oral PROTACs®?
    Jimenez DG; Sebastiano MR; Caron G; Ermondi G
    ADMET DMPK; 2021; 9(4):243-254. PubMed ID: 35300370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational Sampling Deciphers the Chameleonic Properties of a VHL-Based Degrader.
    Ermondi G; Jimenez DG; Rossi Sebastiano M; Kihlberg J; Caron G
    Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refinement of Computational Access to Molecular Physicochemical Properties: From Ro5 to bRo5.
    Rossi Sebastiano M; Garcia Jimenez D; Vallaro M; Caron G; Ermondi G
    J Med Chem; 2022 Sep; 65(18):12068-12083. PubMed ID: 36094896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solution Conformations Explain the Chameleonic Behaviour of Macrocyclic Drugs.
    Danelius E; Poongavanam V; Peintner S; Wieske LHE; Erdélyi M; Kihlberg J
    Chemistry; 2020 Apr; 26(23):5231-5244. PubMed ID: 32027758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solubility prediction in the bRo5 chemical space: where are we right now?
    Ermondi G; Poongavanam V; Vallaro M; Kihlberg J; Caron G
    ADMET DMPK; 2020; 8(3):207-214. PubMed ID: 35300306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steering New Drug Discovery Campaigns: Permeability, Solubility, and Physicochemical Properties in the bRo5 Chemical Space.
    Caron G; Kihlberg J; Goetz G; Ratkova E; Poongavanam V; Ermondi G
    ACS Med Chem Lett; 2021 Jan; 12(1):13-23. PubMed ID: 33488959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degraders early developability assessment: face-to-face with molecular properties.
    Ermondi G; Vallaro M; Caron G
    Drug Discov Today; 2020 Sep; 25(9):1585-1591. PubMed ID: 32565163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space.
    Poongavanam V; Doak BC; Kihlberg J
    Curr Opin Chem Biol; 2018 Jun; 44():23-29. PubMed ID: 29803972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Flexible-Acceptor" General Solubility Equation for beyond Rule of 5 Drugs.
    Avdeef A; Kansy M
    Mol Pharm; 2020 Oct; 17(10):3930-3940. PubMed ID: 32787270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
    Doak BC; Over B; Giordanetto F; Kihlberg J
    Chem Biol; 2014 Sep; 21(9):1115-42. PubMed ID: 25237858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design Principles for Balancing Lipophilicity and Permeability in beyond Rule of 5 Space.
    Möbitz H
    ChemMedChem; 2024 Mar; 19(5):e202300395. PubMed ID: 37986275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five.
    Stegemann S; Moreton C; Svanbäck S; Box K; Motte G; Paudel A
    Drug Discov Today; 2023 Feb; 28(2):103344. PubMed ID: 36442594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current advances and development strategies of orally bioavailable PROTACs.
    Zeng S; Ye Y; Xia H; Min J; Xu J; Wang Z; Pan Y; Zhou X; Huang W
    Eur J Med Chem; 2023 Dec; 261():115793. PubMed ID: 37708797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.